Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01316432 · ClinicalTrials.gov registry record · Phase 1

PK/PD Study of Subcutaneous Cenderitide Infusion in CHF Patients

A Phase 1 study of Heart Failure and Chronic Heart Failure, sponsored by Nile Therapeutics.

Completed
Registry status
Phase 1
Development phase
58
Enrollment target
5
Study locations

NCT01316432: Completed Phase 1 study of Heart Failure and Chronic Heart Failure, sponsored by Nile Therapeutics.

NCT01316432 is a Phase 1 study of Heart Failure and Chronic Heart Failure that has completed, run by Nile Therapeutics. The registered enrollment target is 58 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (97% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01316432, a Phase 1 study of Heart Failure and Chronic Heart Failure, has completed, sponsored by Nile Therapeutics.

COMPLETED
Registry status
Phase 1
Development phase
58 participants
Enrollment target
5
Study locations

Study Summary

The purposed of the study is to evaluate the pharmacokinetics (PK) response of continuous subcutaneous (SQ) infusion of cenderitide, as compared with a single SQ bolus.

Primary Outcome

Pharmacokinetic measurements of subcutaneous cenderitide infusion compared with a subcutaneous bolus administration

Conditions Studied

Heart Failure Chronic Heart Failure CHF ADHF

Interventions

  • OTHER Placebo
  • DRUG Cenderitide

Study Locations (5)

California

  • Orange County Research Center - Tustin

Florida

  • Jacksonville Center for Clinical Research - Jacksonville

Kansas

  • Analab Clinical Research, Inc. - Lenexa

Louisiana

  • Benchmark Research - Metairie

Minnesota

  • Hennepin County Medical Center - Minneapolis

Trial Details

FieldValue
Enrollment Target 58 participants
Start Date 2011-05
Est. Completion 2011-11
Phase Phase 1
Nile Therapeutics

3 total trials

What the finished NCT01316432 record still lists

NCT01316432 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (97% lower).

The record links to 4 conditions, with Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT01316432 lists 5 locations in 5 states (California, Florida, Kansas).

Frequently Asked Questions

What is clinical trial NCT01316432 about?

NCT01316432 is a clinical study titled "PK/PD Study of Subcutaneous Cenderitide Infusion in CHF Patients". The purposed of the study is to evaluate the pharmacokinetics (PK) response of continuous subcutaneous (SQ) infusion of cenderitide, as compared with a single SQ bolus.

What is the current status of trial NCT01316432?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2011-05. Estimated completion is 2011-11.

What conditions does trial NCT01316432 study?

This clinical trial studies the following conditions: Heart Failure, Chronic Heart Failure, CHF, ADHF.

What interventions are being tested in trial NCT01316432?

The interventions under investigation include: Placebo (OTHER), Cenderitide (DRUG).

Who is sponsoring clinical trial NCT01316432?

This trial is sponsored by Nile Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01316432 being conducted?

This trial has 5 study locations across California, Florida, Kansas, Louisiana, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01316432's enrollment target sits among peer trials

58 268th of 397 higher than 130 of 397 other Heart Failure trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03587844 · 58 participants · Phase 2

    Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

  • NCT03630991 · 58 participants · Phase 1

    Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy

  • NCT03949855 · 58 participants · Phase 2

    Belimumab With Rituximab for Primary Membranous Nephropathy

  • NCT04069273 · 58 participants · Phase 2

    Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT01316432, the US trial registry maintained by the National Library of Medicine. NCT01316432 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.